Clinipace Worldwide, a global digital CRO, has completed its merger with Accovion, headquartered in Frankfurt, Germany. Terms of the transaction were not disclosed. 
 
Accovion provides a range of clinical research services to the pharmaceutical, biotechnology and medical device industries across all phases of clinical development, and is currently active in more than 20 countries. The acquisition expands Clinipace’s footprint to countries including Russia, Italy, Czech Republic, Romania, Poland, Spain, France and Ukraine. 
 
Dr. Andree Beckerling, the chief executive officer of Accovion, will have day-to-day operating responsibility for all of the European offices, including existing Clinipace staff and locations. Dr. Beckerling will report to Clinipace chief executive officer, Jeff Williams, and will join the company’s executive committee.
 
“Life science firms, and the CRO industry that serves them, continue to undergo significant change. To be competitive in today’s market, it is important to have, among other things, a strong multi-national scale, broad therapeutic expertise and a better service delivery model,” said Mr. Williams of Clinipace. “Bringing our companies together substantially enhances our existing European footprint throughout western, central and Eastern Europe and enables us to offer a competitive array of global clinical development and regulatory services in these regions. Supported by our technology-amplified dCRO delivery model, we now have a very compelling value proposition for sponsors looking for support in these markets.”